An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes, in miscellaneous provisions, further providing for urine drug screening requirement and providing for medetomidine awareness education.

SB 865 requires emergency departments in Pennsylvania hospitals to test patient urine samples for fentanyl, medetomidine, and xylazine when conducting drug screenings for diagnosis, provided such testing is available. It mandates reporting positive results (meeting department-set thresholds) to the Department of Health, with deidentified data used for awareness efforts. The bill also creates a new requirement for the Department of Drug and Alcohol Programs to develop educational materials about the dangers of human medetomidine use - highlighting its veterinary origins, health effects, and how to discuss risks with others. These provisions directly affect emergency departments, patients receiving screenings, and residents through public health education. The law takes effect 60 days after enactment.